Skip to main content
Premium Trial:

Request an Annual Quote

NHGRI Asks for Community's Input on BD2K Data Handling Approaches

Premium

The National Human Genome Research Institute issued a request for information this week that asks the research community to submit ideas for methods of data compression and reduction, visualization, provenance, and wrangling as part of its Big Data to Knowledge, or BD2K, Initiative.

Community members are asked to respond to the RFI by Sept. 6, 2013.

BD2K is one of two proposed initiatives that the data and informatics working group of the National Institutes of Health’s Advisory Committee to the Director proposed last year to help the institute better handle the data generated by biomedical research projects it supports (BI 12/14/2012).

It issued an RFI in February asking for the community's help in developing training programs as part of the initiative (BI 2/22/2013). Another RFI in June asked for help in putting together a proposal to develop a biomedical data catalog that will make it easier to find, share, and cite research data (BI 6/14/2013).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.